Pictet Asset Management
MYGN icon

Pictet Asset Management’s Myriad Genetics MYGN Stock Holding History

Pictet Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,224
Closed -$59.5K – 2184
2026
Q1 		$59.5K Hold
13,224
– – ﹤0.01% 2078
2025
Q4 		$81.3K Hold
13,224
– – ﹤0.01% 2044
2025
Q3 		$95.6K Hold
13,224
– – ﹤0.01% 1984
2025
Q2 		$70.2K Hold
13,224
– – ﹤0.01% 1973
2025
Q1 		$117K Sell
13,224
-466,584
-97% -$5.6M ﹤0.01% 1901
2024
Q4 		$6.58M Sell
479,808
-36,262
-7% -$669K 0.01% 759
2024
Q3 		$13.7M Sell
516,070
-27,418
-5% -$742K 0.02% 577
2024
Q2 		$13.3M Sell
543,488
-670,828
-55% -$14.7M 0.02% 572
2024
Q1 		$25.9M Sell
1,214,316
-80,458
-6% -$1.73M 0.03% 429
2023
Q4 		$24.8M Buy
1,294,774
+76,528
+6% +$1.32M 0.03% 427
2023
Q3 		$19.5M Buy
+1,218,246
New +$23.2M 0.02% 465

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pictet Asset Management's MYGN Position: Q2 2026 in Review

Pictet Asset Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 13,224 shares — an estimated $59.5K sold.

Pictet Asset Management first reported a position in MYGN in Q3 2023 and held it in 11 quarters. The position peaked at $25.9M in Q1 2024. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Pictet Asset Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Pictet Asset Management sold 13,224 Myriad Genetics shares in Q2 2026, an estimated $59.5K.
  • Pictet Asset Management first reported a position in Myriad Genetics in Q3 2023 and held it in 11 quarters.
  • Pictet Asset Management's Myriad Genetics position peaked at $25.9M in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.